Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Circovac   
Auth. number : EU/2/07/075
Active substance : Not available
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI09 - Immunologicals for suidae
Pharmacological subgroup: QI09A - Pig
Chemical subgroup: QI09AA - Inactivated viral vaccines
Chemical substance: QI09AA07 - porcine circovirus
(See WHO ATCvet Index)
Indication: Piglets: Active immunisation of piglets to reduce faecal excretion of PCV2 and virus load in blood, and as an aid to reduce PCV2 linked clinical signs, including wasting, weight loss and mortality as well as to reduce virus load and lesions in lymphoid tissues associated with PCV2 infection.
Onset of immunity: 2 weeks.
Duration of immunity: at least 14 weeks after vaccination.
Sows and gilts: Passive immunisation of piglets via the colostrum, after active immunisation of sows and gilts, to reduce lesions in lymphoid tissues associated with PCV2 infection and as an aid to reduce PCV2-linked mortality.
Duration of immunity: up to 5 weeks after transfer of passive antibodies through colostrum intake.
Marketing Authorisation Holder: Ceva-Phylaxia Zrt.
Szállás u. 5, 1107 Budapest, Magyarország
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/06/2007 Centralised - Authorisation EMEA/V/C/114 (2007)3140 of 21/06/2007
27/08/2008 Centralised - Variation EMEA/V/C/114/II/1 (2008)4674 of 25/08/2008
19/11/2008 Centralised - Variation EMEA/V/C/114/IB/2
Updated with Decision(2009)4583 of 08/06/2009
10/06/2009 Centralised - Variation (2009)4583 of 8/06/2009
24/07/2009 Centralised - Variation (no change in Commission Decision) EMEA/V/C/114/II/3
24/09/2009 Centralised - Variation (no change in Commission Decision) EMEA/V/C/114/II/4
3/12/2010 Centralised - Variation EMEA/V/C/114/II/5 (2010)8649 of 29/11/2010
10/05/2011 Centralised - Variation EMEA/V/C/114/IB/6/G
Updated with Decision(2011)9183 of 05/12/2011
7/12/2011 Centralised - Variation (2011)9183 of 5/12/2011
14/05/2012 Centralised - Renewal EMEA/V/C/114/R/7 (2012)3217 of 10/05/2012
16/05/2013 Centralised - Variation EMEA/V/C/114/II/8
Updated with Decision(2014)3417 of 16/05/2014
20/05/2014 Centralised - Yearly update (2014)3417 of 16/05/2014
22/02/2017 Centralised - Variation EMEA/V/C/114/IA/13/G
Updated with Decision(2017)7893 of 21/11/2017
15/06/2017 Centralised - Transfer Marketing Authorisation Holder EMEA/V/C/114/T/14 (2017)4203 of 13/06/2017
23/11/2017 Centralised - Transfer Marketing Authorisation Holder EMEA/V/C/114/T/14 (2017)7893 of 21/11/2017